Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
19 hedge funds and large institutions have $7.5M invested in Timber Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.11% less ownership
Funds ownership: 17.85% → 17.74% (-0.11%)
4% less capital invested
Capital invested by funds: $7.83M → $7.5M (-$331K)
10% less funds holding
Funds holding: 21 → 19 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$101K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$40.5K |
| 3 |
VF
Virtu Financial
New York
|
+$37.1K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$10.1K |
| 5 |
LFAS
Level Four Advisory Services
Dallas,
Texas
|
+$3.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$91.1K |
| 2 |
MA
MCF Advisors
Covington,
Kentucky
|
-$24K |
| 3 |
Jane Street
New York
|
-$22K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$22K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$13.5K |
TMBR Hedge Fund Activity: Q2 2018 in Review
19 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2018, worth a combined $7.5M — down 4.2% from $7.83M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TMBR and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Barclays, adding an estimated $101K. The largest seller was Vanguard Group, cutting an estimated $91.1K.
- 19 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2018, down from 21 in Q1 2018.
- Funds reported $7.5M of Timber Pharmaceuticals, Inc. stock for Q2 2018, down 4.2% quarter-over-quarter.
- 2 funds opened new Timber Pharmaceuticals, Inc. positions in Q2 2018 and 4 closed out, a net change of -2 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q2 2018 was Barclays, an estimated $101K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q2 2018 was Vanguard Group, an estimated $91.1K sold.
Based on aggregated 13F filings for Q2 2018.